ライフサイエンスコーパス: obstructive sleep apnea

1 ationale for a new pharmacologic therapy for obstructive sleep apnea.

2 latively well-controlled type 2 diabetes and obstructive sleep apnea.

3 icular emphasis on children with more severe obstructive sleep apnea.

4 or socioeconomic factors and the presence of obstructive sleep apnea.

5 ence of diabetes mellitus, hypertension, and obstructive sleep apnea.

6 tory of diabetes mellitus, hypertension, and obstructive sleep apnea.

7 nasal flow monitor for 1 night to assess for obstructive sleep apnea.

8 d subjective measurements of the severity of obstructive sleep apnea.

9 nths for the treatment of moderate-to-severe obstructive sleep apnea.

10 diagnostic testing in patients suspected of obstructive sleep apnea.

11 s esophagus subjects scored at high risk for obstructive sleep apnea.

12 ambulatory models of care for patients with obstructive sleep apnea.

13 ere associated with scoring at high risk for obstructive sleep apnea.

14 rument identifying subjects at high risk for obstructive sleep apnea.

15 ved risk outcomes associated with asthma and obstructive sleep apnea.

16 y of symptoms and signs for the diagnosis of obstructive sleep apnea.

17 me of sleepy patients with mild and moderate obstructive sleep apnea.

18 neck circumference (NC) and with severity of obstructive sleep apnea.

19 n undergoing adenoidectomy for chronic OM or obstructive sleep apnea.

20 ertension and primary aldosteronism and with obstructive sleep apnea.

21 patients with resistant hypertension, as is obstructive sleep apnea.

22 IF-2a should minimize motoneuronal injury in obstructive sleep apnea.

23 ance of assessing physiological variation in obstructive sleep apnea.

24 poxia (CIH) simulating a severe condition of obstructive sleep apnea.

25 eeSurfer revealed increased gray matter with obstructive sleep apnea.

26 ovascular and cognitive consequences seen in obstructive sleep apnea.

27 isms attributed to a presymptomatic stage of obstructive sleep apnea.

28 ies to unveil its potential for reduction of obstructive sleep apneas.

29 t), body mass index >/=25kg/m(2) (+1 point), obstructive sleep apnea (+1 point), gastroesophageal ref

30 ehypertension, 15 of 18 (83.3%); symptoms of obstructive sleep apnea, 20 of 22 (90.9%); diabetes, 15

31 l cohort, 1666 (33.6%) screened positive for obstructive sleep apnea, 281 (6.5%) for moderate to seve

32 ), hypertension (2.94 vs 2.80, P = .75), and obstructive sleep apnea (3.29 vs 2.83, P = .50).

33 tory patients with OHS and coexistent severe obstructive sleep apnea, 4) patients hospitalized with r

34 ion in facility revenue, 48 cases of cure of obstructive sleep apnea, 44 cases of remission of type 2

35 d Main Results: A total of 268 patients with obstructive sleep apnea (75% male; mean age, 52 yr; apne

36 The percentage of children with obstructive sleep apnea (8.2% of caffeine group versus 1

37 r control is critical to the pathogenesis of obstructive sleep apnea, a common and serious sleep-rela

38 Community and referral-based prevalence of obstructive sleep apnea; accuracy of symptoms and signs

39 We found a link between obstructive sleep apnea and an elevated risk of stage 3

40 en made in defining the relationship between obstructive sleep apnea and cardiovascular disease.

41 hanistic and empirical bases for considering obstructive sleep apnea and central sleep apnea associat

42 Given the high prevalence of obstructive sleep apnea and CKD among adults, further in

43 a under 3 years of age and those with severe obstructive sleep apnea and comorbidities are not candid

44 and reduced sleepiness in participants with obstructive sleep apnea and excessive sleepiness; most a

45 y driving, and the common sleep disorders of obstructive sleep apnea and insomnia.

46 ht and poor bone density; high prevalence of obstructive sleep apnea and its implications; prevalence

47 eruse headache, temporomandibular disorders, obstructive sleep apnea and obesity.

48 gardless of caffeine status, are at risk for obstructive sleep apnea and periodic limb movements in l

49 N), type II diabetes mellitus, dyslipidemia, obstructive sleep apnea and sleep-disordered breathing,

50 gus patients have an increased likelihood of obstructive sleep apnea and to determine whether nocturn

51 Patients with obstructive sleep apnea and/or obesity have high atrial

52 Patients with obstructive sleep apnea and/or obesity have less freedom

53 tions including high altitude, lung disease, obstructive sleep apnea, and age-related CNS ischemia/hy

54 icularly in children with moderate to severe obstructive sleep apnea, and also that even snoring alon

55 estyle, smoking, obesity, diabetes mellitus, obstructive sleep apnea, and elevated blood pressure pre

56 pertension, diabetes mellitus, inflammation, obstructive sleep apnea, and others.

57 with other sleep disorders (e.g., insomnia, obstructive sleep apnea, and parasomnias).

58 81 patients with obesity, moderate-to-severe obstructive sleep apnea, and serum levels of C-reactive

59 Thirteen male participants with obstructive sleep apnea (apnea-hypopnea index > 5 events

60 s those associated with myocardial infarcts, obstructive sleep apneas, apneas of prematurity, Rett sy

61 s have opposite hemodynamic effects: whereas obstructive sleep apnea appears to have an adverse effec

62 neas during sleep in patients suffering from obstructive sleep apnea are not well understood.

63 Treatment options for infant obstructive sleep apnea are predicated on the underlying

64 idelines for the diagnosis and management of obstructive sleep apnea are reviewed, as are recent guid

65 discuss the relationship between obesity and obstructive sleep apnea as they relate to the growing at

66 demographics and lifestyle behaviors, severe obstructive sleep apnea associated with increased risk o

67 table hypercapnic COPD undergo screening for obstructive sleep apnea before initiation of long-term N

68 Among patients with obstructive sleep apnea, both CPAP and MADs were associa

69 management of more symptomatic patients with obstructive sleep apnea, but its effectiveness has not b

70 Rationale: Primary treatment of obstructive sleep apnea can be accompanied by a persiste

71 vity.SIGNIFICANCE STATEMENT Individuals with obstructive sleep apnea can breathe adequately when awak

72 and treatment of hypertension, diabetes, and obstructive sleep apnea can reduce atrial fibrillation e

73 RATIONALE: Obstructive sleep apnea causes intermittent hypoxemia, h

74 ett's esophagus and scoring at high risk for obstructive sleep apnea compared with colonoscopy patien

75 s esophagus subjects scored at high risk for obstructive sleep apnea, compared with 42% (n = 26) of E

76 In adults with obesity and obstructive sleep apnea, CPAP combined with a weight-los

77 During obstructive sleep apnea, elevation of CO(2) during apnea

78 s diabetes mellitus, chronic kidney disease, obstructive sleep apnea, etc.

79 suppressed, and as a result individuals with obstructive sleep apnea experience repeated episodes of

80 This issue provides a clinical overview of Obstructive Sleep Apnea focusing on prevention, diagnosi

81 n used as a treatment option for snoring and obstructive sleep apnea for almost three decades.

82 e prehypertension, increased pulse pressure, obstructive sleep apnea, high-level physical training, d

83 patient-level factors that included obesity, obstructive sleep apnea, higher comorbidity, and use of

84 cators of obstruction sites in patients with obstructive sleep apnea hypopnea syndrome (OSAHS).

85 research highlights the interactions between obstructive sleep apnea-hypopnea syndrome (OSAHS) and ca

86 the set of patient generated health data, an obstructive sleep apnea-hypopnea syndrome (OSAHS) monito

87 inflammatory disease, diabetes mellitus, or obstructive sleep apnea (ie, lone AF) undergoing ablatio

88 clinical recommendations on the diagnosis of obstructive sleep apnea in adults.

89 pressure therapy is frequently used to treat obstructive sleep apnea in children.

90 hypoxia (CIH), an animal model for studying obstructive sleep apnea in humans, depresses the afferen

91 sleep and is a cause of hypoventilation and obstructive sleep apnea in humans.

92 Obstructive sleep apnea in infants has a distinctive pat

93 Obstructive sleep apnea in infants has been associated w

94 Initial studies addressing the presence of obstructive sleep apnea in patients undergoing upper end

95 nto the neck in association with less severe obstructive sleep apnea in women than in men with heart

96 ht fluid shift from the legs and severity of obstructive sleep apnea in women than in men with heart

97 Obstructive sleep apnea is a common disease, responsible

98 Obstructive sleep apnea is a common disorder associated

99 Obstructive sleep apnea is a diagnosis that ophthalmolog

100 Obstructive sleep apnea is a risk factor for dyslipidemi

101 Obstructive sleep apnea is a risk factor for mortality,

102 Obstructive sleep apnea is a state-dependent disease.

103 Obstructive sleep apnea is associated with an increased

104 ervational studies in men have reported that obstructive sleep apnea is associated with an increased

105 Obstructive sleep apnea is associated with considerable

106 Obstructive sleep apnea is associated with higher levels

107 Obstructive sleep apnea is associated with hypertension,

108 Epidemiological research indicates that obstructive sleep apnea is associated with increases in

109 A growing population of patients with obstructive sleep apnea is being referred for outpatient

110 Pediatric obstructive sleep apnea is discussed.

111 Because the prevalence of obstructive sleep apnea is lower in women than in men wi

112 Obstructive sleep apnea is primarily characterized by hy

113 nical examination of patients with suspected obstructive sleep apnea is useful for selecting patients

114 Despite the high prevalence of obstructive sleep apnea, it was not associated with the

115 importance of genetic factors in influencing obstructive sleep apnea, its genetic basis is still larg

116 n 26 are unlikely to have moderate or severe obstructive sleep apnea (LR, 0.07; 95% CI, 0.03-0.19 at

117 Obstructive sleep apnea may be associated with developme

118 Prior studies suggest that obstructive sleep apnea may be associated with gastroeso

119 Obstructive sleep apnea may be associated with preclinic

120 is uncertainty about the effects of treating obstructive sleep apnea on glycemic control in patients

121 Respondents who screened positive for obstructive sleep apnea or any sleep disorder had an inc

122 h secondary causes of hypertension including obstructive sleep apnea or primary aldosteronism.

123 tal health and psychological issues, asthma, obstructive sleep apnea, orthopedic problems, and advers

124 Obstructive sleep apnea (OSA) affects 17% of women and 3

125 Obstructive sleep apnea (OSA) affects 8-10% of the popul

126 mechanism underlying the association between obstructive sleep apnea (OSA) and Alzheimer's disease is

127 Obstructive sleep apnea (OSA) and asthma are highly prev

128 provide an update on the connection between obstructive sleep apnea (OSA) and cardiovascular disease

129 The relationship between obstructive sleep apnea (OSA) and cardiovascular events

130 f intermittent hypoxia (IH) in patients with obstructive sleep apnea (OSA) and cutaneous melanoma (CM

131 tudies report a positive association between obstructive sleep apnea (OSA) and glaucoma; larger, retr

132 Obstructive sleep apnea (OSA) and nocturnal hypoxemia ar

133 Risk factors for obstructive sleep apnea (OSA) and the development of sub

134 els for surgical patients who have suspected obstructive sleep apnea (OSA) at risk for postoperative

135 Treatment is needed for obstructive sleep apnea (OSA) because untreated OSA can

136 Surgical success for obstructive sleep apnea (OSA) depends on identifying sit

137 based on pharyngeal factors is important for obstructive sleep apnea (OSA) evaluation.

138 , chronic obstructive pulmonary disease, and obstructive sleep apnea (OSA) exhibit daily variance.

139 Obstructive sleep apnea (OSA) has been associated with i

140 A high prevalence of obstructive sleep apnea (OSA) has been reported in Down

141 ssible association between periodontitis and obstructive sleep apnea (OSA) has been suggested.

142 Traditionally, the presence and severity of obstructive sleep apnea (OSA) have been defined by the a

143 linical recommendations on the management of obstructive sleep apnea (OSA) in adults.

144 An adverse role for obstructive sleep apnea (OSA) in cancer epidemiology and

145 data from the 1990s, estimated prevalence of obstructive sleep apnea (OSA) in the United States is 10

146 Obstructive sleep apnea (OSA) increases risk of dementia

147 We determine whether obstructive sleep apnea (OSA) increases serum levels of

148 Obstructive sleep apnea (OSA) is a common disorder assoc

149 Obstructive sleep apnea (OSA) is a common sleep disorder

150 Mild obstructive sleep apnea (OSA) is a highly prevalent diso

151 Obstructive sleep apnea (OSA) is a highly prevalent diso

152 Obstructive sleep apnea (OSA) is a known risk factor for

153 Obstructive sleep apnea (OSA) is a low-grade inflammator

154 Obstructive sleep apnea (OSA) is a risk factor for cardi

155 Obstructive sleep apnea (OSA) is a risk factor for cardi

156 Obstructive sleep apnea (OSA) is a risk factor for type

157 Obstructive sleep apnea (OSA) is a sleep disorder charac

158 Obstructive sleep apnea (OSA) is a very prevalent disord

159 Obstructive sleep apnea (OSA) is a worldwide disease who

160 Obstructive sleep apnea (OSA) is also common in patients

161 Obstructive sleep apnea (OSA) is an underdiagnosed condi

162 Obstructive sleep apnea (OSA) is associated with atrial

163 Obstructive sleep apnea (OSA) is associated with cardiov

164 Obstructive sleep apnea (OSA) is associated with hyperte

165 Although obstructive sleep apnea (OSA) is associated with impaire

166 Rationale: Obstructive sleep apnea (OSA) is associated with increas

167 RATIONALE: Obstructive sleep apnea (OSA) is associated with several

168 Obstructive sleep apnea (OSA) is associated with systemi

169 Recent studies have demonstrated that obstructive sleep apnea (OSA) is associated with the dev

170 Obstructive sleep apnea (OSA) is characterized by recurr

171 Obstructive sleep apnea (OSA) is characterized by recurr

172 Obstructive sleep apnea (OSA) is characterized by repeti

173 Obstructive sleep apnea (OSA) is common in patients with

174 Obstructive sleep apnea (OSA) is common in people with h

175 Unrecognized obstructive sleep apnea (OSA) is highly prevalent in obe

176 Obstructive sleep apnea (OSA) is linked to increased gla

177 Obstructive sleep apnea (OSA) is more common among patie

178 Obstructive sleep apnea (OSA) is strongly related to obe

179 Obstructive sleep apnea (OSA) is the most common medical

180 oratory polysomnography (PSG) for diagnosing obstructive sleep apnea (OSA) is unclear.

181 Obstructive sleep apnea (OSA) is very common but is freq

182 Pediatric obstructive sleep apnea (OSA) leads to multiple end-orga

183 It is unknown whether obstructive sleep apnea (OSA) may be a risk factor for i

184 Despite emerging evidence that obstructive sleep apnea (OSA) may cause metabolic distur

185 mpact of intracranial hypertension (ICH) and obstructive sleep apnea (OSA) on optic nerve function in

186 ory event index (REI) in moderate and severe obstructive sleep apnea (OSA) patients requires elucidat

187 The authors tested the hypothesis that obstructive sleep apnea (OSA) signs/symptoms are associa

188 The effect of obstructive sleep apnea (OSA) syndrome in the peripapill

189 ibrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein

190 Many adults with obstructive sleep apnea (OSA) use device treatments inad

191 Moderate or severe obstructive sleep apnea (OSA) was defined as a respirato

192 Previous studies in obstructive sleep apnea (OSA) were limited by study coho

193 We recruited subjects with severe obstructive sleep apnea (OSA) who were well treated and

194 hypoxia (IH) is a hallmark manifestation of obstructive sleep apnea (OSA), a widespread disorder of

195 stless legs syndrome (RLS), 21 patients with obstructive sleep apnea (OSA), and 19 healthy volunteers

196 hildren are at increased risk for developing obstructive sleep apnea (OSA), and both of these conditi

197 P) is considered the treatment of choice for obstructive sleep apnea (OSA), and studies have shown th

198 Childhood asthma and obstructive sleep apnea (OSA), both disorders of airway

199 Sleep abnormalities, including obstructive sleep apnea (OSA), have been associated with

200 atients with resistant hypertension (RH) and obstructive sleep apnea (OSA), the blood pressure respon

201 ationship between floppy eyelid syndrome and obstructive sleep apnea (OSA), the diagnostic criteria o

202 s positive airway pressure for patients with obstructive sleep apnea (OSA).

203 tment of choice in patients with symptomatic obstructive sleep apnea (OSA).

204 herapy is the most common treatment used for obstructive sleep apnea (OSA).

205 decades ago, we evaluated ten patients with obstructive sleep apnea (OSA).

206 nale: Obesity is the primary risk factor for obstructive sleep apnea (OSA).

207 Body habitus is a major determinant of obstructive sleep apnea (OSA).

208 ty of the tongue is unknown in patients with obstructive sleep apnea (OSA).

209 by routine imaging methods in patients with obstructive sleep apnea (OSA).

210 ased prevalence of glaucoma in patients with obstructive sleep apnea (OSA).

211 patients with chronic insomnia disorder and obstructive sleep apnea (OSA).

212 f sudden cardiac death (SCD) associated with obstructive sleep apnea (OSA).

213 of patients with resistant hypertension have obstructive sleep apnea (OSA).

214 ice (MAD) therapy are commonly used to treat obstructive sleep apnea (OSA).

215 line treatment for patients with symptomatic obstructive sleep apnea (OSA).

216 ypertension is prevalent among patients with obstructive sleep apnea (OSA).

217 (b) Obstructive sleep apnea (OSA).

218 S is a common symptom of both narcolepsy and obstructive sleep apnea (OSA).

219 y no effective pharmacological treatment for obstructive sleep apnea (OSA).

220 ical and population samples of patients with obstructive sleep apnea (OSA).

221 retinal vascular caliber and the severity of obstructive sleep apnea (OSA).

222 adverse health outcomes are associated with obstructive sleep apnea (OSA).

223 n human subjects with high and low risks for obstructive sleep apnea (OSA).

224 ascular events, is linked to the severity of obstructive sleep apnea (OSA).

225 ay represent a critical pathology underlying obstructive sleep apnea (OSA).

226 Obstructive sleep apnea(OSA) is one of the most common s

227 We examined the association between obstructive sleep apnea, other sleep characteristics, an

228 ificantly less improvement in ACT scores was obstructive sleep apnea (P = 0.016).

229 (ArTH) is one of several traits involved in obstructive sleep apnea pathogenesis and may be a therap

230 stoperative discharge criteria, care for the obstructive sleep apnea patient, and the choice of anest

231 to two different definitions for positional obstructive sleep apnea (POSA).

232 Obstructive sleep apnea predicted incident heart failure

233 addition, sleep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavi

234 eepiness in patients with moderate to severe obstructive sleep apnea refusing continuous positive air

235 nome-level significant findings reported for obstructive sleep apnea-related physiologic traits in an

236 tal disorder and due to a medical condition, obstructive sleep apnea, restless legs syndrome, idiopat

237 abetes mellitus, cardiovascular disease, and obstructive sleep apnea, resulting in significant health

238 It is anticipated that obstructive sleep apnea results in endoplasmic reticulum

239 relationship between Barrett's esophagus and obstructive sleep apnea risk.

240 The need for obstructive sleep apnea screening in Barrett's esophagus

241 n gray matter characteristics and markers of obstructive sleep apnea severity (hypoxemia, respiratory

242 a-hypopnea index (events per hour) to define obstructive sleep apnea severity (normal, <5.0; mild, 5.

243 To investigate whether markers of obstructive sleep apnea severity are associated with gra

244 onal hazards regression was used to estimate obstructive sleep apnea severity with risk of incident C

245 ts for definitive testing, the likelihood of obstructive sleep apnea should be established in the cli

246 idence to recommend the routine treatment of obstructive sleep apnea specifically for the prevention

247 ecific and general quality of life measures, obstructive sleep apnea symptoms, adherence to using con

248 Many patients with obstructive sleep apnea syndrome (OSA) living near sea l

249 Obstructive sleep apnea syndrome (OSAS) and nonalcoholic

250 ronic intermittent hypoxia (CIH) occurs with obstructive sleep apnea syndrome (OSAS) and provokes sys

251 The prevalence of obstructive sleep apnea syndrome (OSAS) in patients with

252 Obstructive sleep apnea syndrome (OSAS) is associated wi

253 Obstructive sleep apnea syndrome (OSAS) leads to neuroco

254 e are also a few studies suggesting that the obstructive sleep apnea syndrome (OSAS) may compromise o

255 Obstructive sleep apnea syndrome (OSAS) represents a sub

256 aims to investigate the correlation between obstructive sleep apnea syndrome (OSAS) risk with period

257 e (CPAP) in asthma patients with concomitant obstructive sleep apnea syndrome (OSAS) seems to have a

258 l disease has been reported in patients with obstructive sleep apnea syndrome (OSAS), and these two c

259 ), which includes primary snoring through to obstructive sleep apnea syndrome (OSAS), may cause compr

260 therapy plays a role in treating snoring and obstructive sleep apnea syndrome (OSAS).

261 ucture, hippocampus-dependent cognition, and obstructive sleep apnea syndrome (OSAS).

262 x, age, systemic hypertension, diabetes, and obstructive sleep apnea syndrome between September 2007

263 We have observed a significant prevalence of obstructive sleep apnea syndrome in patients in waiting

264 watchful waiting, surgical treatment for the obstructive sleep apnea syndrome in school-age children

265 Obstructive sleep apnea syndrome is a highly prevalent d

266 464 children, 5 to 9 years of age, with the obstructive sleep apnea syndrome to early adenotonsillec

267 Prevalence of obstructive sleep apnea syndrome was 38% before the LT,

268 We hypothesized that, in children with the obstructive sleep apnea syndrome without prolonged oxyhe

269 ncluded obesity (body mass index [BMI] >35), obstructive sleep apnea syndrome, or other causes of res

270 ated to patient (Mallampati score III or IV, obstructive sleep apnea syndrome, reduced mobility of ce

271 y is commonly performed in children with the obstructive sleep apnea syndrome, yet its usefulness in

272 ry heart disease, migraine, hypotension, and obstructive sleep apnea syndrome.

273 essure in asthmatics with moderate to severe obstructive sleep apnea syndrome.

274 sleepiness is a common disabling symptom in obstructive sleep apnea syndrome.Objectives: To evaluate

275 Obesity and obstructive sleep apnea tend to coexist and are associat

276 s were more likely to score at high risk for obstructive sleep apnea than patients without nocturnal

277 nferiority study involving 155 patients with obstructive sleep apnea that was treated at primary care

278 ader on the most recent developments linking obstructive sleep apnea to cardiovascular disease.

279 of this study was to assess the relation of obstructive sleep apnea to incident coronary heart disea

280 Among patients with obstructive sleep apnea, treatment under a primary care

281 Children with obstructive sleep apnea under 3 years of age and those w

282 Primary care management of obstructive sleep apnea vs usual care in a specialist sl

283 Prevalence of severe obstructive sleep apnea was 51% (95% confidence interval

284 After adjustment for multiple risk factors, obstructive sleep apnea was a significant predictor of i

285 The severity of obstructive sleep apnea was assessed by the apnea-hypopn

286 Obstructive sleep apnea was diagnosed when the AHI was 1

287 ul observation for identifying patients with obstructive sleep apnea was nocturnal choking or gasping

288 221 patients with OHS and coexistent severe obstructive sleep apnea), we compared the effectiveness

289 Rates of scoring at high risk for obstructive sleep apnea were compared.

290 an inactive control) on BP in patients with obstructive sleep apnea were selected by consensus.

291 uch as smokers, diabetics, and subjects with obstructive sleep apnea, where their prolonged contact w

292 or choking is the most reliable indicator of obstructive sleep apnea, whereas snoring is not very spe

293 The presence of obstructive sleep apnea whether diagnosed by a surrogate

294 Women with obesity should be screened for obstructive sleep apnea, which is often undiagnosed and

295 r-airway stimulation device in patients with obstructive sleep apnea who had difficulty either accept

296 ll trials provide evidence that treatment of obstructive sleep apnea with continuous positive airway

297 ardiovascular risk factors, the treatment of obstructive sleep apnea with CPAP, but not nocturnal sup

298 of excessive sleepiness in participants with obstructive sleep apnea with current or prior sleep apne

299 Patients were screened for obstructive sleep apnea with the use of the Berlin quest

300 type 2 diabetes and no previous diagnosis of obstructive sleep apnea, with a glycated hemoglobin leve